Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Filtrar resultados de búsqueda
Seleccionar modelos de datos

Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

5 Resultados de la búsqueda.

Informed consent Routine documentation in German hospitals DMI

- 30/7/17 - 1 formulario, 4 itemgroups, 19 items, 2 idiomas

Itemgroups: General information, surgery complications, Information Procedure, Consent

Routine documentation in German hospitals. Source file name: AM050105_Einverständniserklärung_Behandlung. Examplary forms provided by DMI (http://www.dmi.de/).

A Cross-Over Study of Alcohol Effect on the Pharmacokinetics of Carvedilol - 106904 - Pharmacogenetics Research Consent Withdrawal

- 11/1/19 - 1 formulario, 3 itemgroups, 10 items, 1 idioma

Itemgroups: Administrative data, Date of Visit/Assessment, PGx Research Withdrawal of Consent

Study ID: 106904 Clinical Study ID: CRV106904 Study Title: A Randomized, Open-Label, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics of Carvedilol CR Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: carvedilol Trade Name: Coreg CR,Coreg Study Indication: Hypertension

Updated informed consent GSK study Chronic Coronary Heart Disease NCT00799903

- 11/1/18 - 1 formulario, 1 itemgroup, 6 items, 1 idioma

Itemgroup: Updated informed consent

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Updated informed consent

Pharmacogenetic research Withdrawal of consent GSK study Chronic Coronary Heart Disease NCT00799903 - Pharmacogenetic research Withdrawal of consent Subject Identification GSK study Chronic Coronary Heart Disease NCT00799903

- 11/1/18 - 1 formulario, 1 itemgroup, 5 items, 1 idioma

Itemgroup: Withdrawal of consent for PGx (DNA) / Blood sample destruction

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Pharmacogenetic research Withdrawal of consent

A Cross-Over Study of Alcohol Effect on the Pharmacokinetics of Carvedilol - 106904 - Pharmacogenetics Research Consent Form

- 11/1/19 - 1 formulario, 3 itemgroups, 12 items, 1 idioma

Itemgroups: Administrative data, Date of Visit/Assessment, PGx Research Consent

Study ID: 106904 Clinical Study ID: CRV106904 Study Title: A Randomized, Open-Label, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics of Carvedilol CR Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: carvedilol Trade Name: Coreg CR,Coreg Study Indication: Hypertension

Utilice este formulario para comentarios, preguntas y sugerencias.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.